ERP5 Antibody

What is ERp5 and what are its primary biological functions?

ERp5 (Endoplasmic Reticulum Protein 5) is a member of the protein disulfide isomerase family that contains two CXXC-like motifs responsible for oxidoreductase activity . Located primarily in the endoplasmic reticulum and melanosomes, ERp5 plays vital roles in:

• Catalyzing rearrangement of disulfide bonds in proteins, essential for proper protein folding and stability

• Maintaining endoplasmic reticulum homeostasis

• Regulating platelet function and thrombus formation

• Immune system modulation through interaction with cell surface antigens

Unlike most PDI-like proteins, ERp5 is not stress-inducible . The protein contains the ER retention signal KDEL and has both peptide binding ability and chaperone activity specific to certain proteins .

What types of ERp5 antibodies are available for research applications?

Multiple types of ERp5 antibodies are available for research applications:

Most commercially available antibodies target epitopes within the 440-amino acid sequence of the ERp5 protein .

What is the relationship between ERp5 and endoplasmic reticulum (ER) stress?

ERp5 plays a crucial role in regulating ER stress responses. Research has shown that:

• ERp5 inhibits the activation of ER stress sensors including protein kinase RNA-like endoplasmic reticulum kinase and IRE1 in murine platelets

• ERp5 deficiency leads to defective ER homeostasis, which promotes secretion of ER PDIs and chaperones

• In ERp5-deficient platelets, there is a marked two-fold upregulation of ER proteins, including PDI, ERp57, ERp72, ERp46, GRP78, and calreticulin

• ERp5-deficient platelets show enhanced ER stress responses to ex vivo and in vivo ER stress inducers, with increased phosphorylation of eukaryotic translation initiation factor 2A and inositol-requiring enzyme 1

How should I design experiments to study ERp5 function in platelet biology?

When designing experiments to study ERp5 function in platelets, consider the following approach based on recent research methodologies:

• Animal model selection: Use platelet-specific ERp5-knockout mice (e.g., Pf4Cre+/ERp5 fl/fl) to study loss-of-function effects

• Baseline measurements:

  • Complete blood count analysis (WBC, RBC, hemoglobin, platelet count)

  • Platelet size analysis using transmission electron microscopy (TEM)

  • Cytoskeletal staining

  • α and dense granule density measurement

• Functional assays:

  • Platelet aggregation testing

  • Granule secretion measurement

  • Integrin αIIbβ3 activation assessment

  • Tail bleeding time assays

  • FeCl3-induced mesenteric artery injury models for thrombosis

• Molecular analysis:

  • Expression analysis of surface receptors (CD41, CD42c, glycoprotein VI)

  • Analysis of P-selectin and activated αIIbβ3 integrin (JON/A) in response to varying doses of thrombin

Recent studies have revealed that while ERp5-deficient mice have decreased platelet counts, they exhibit enhanced platelet reactivity, shortened tail-bleeding times, and increased thrombus formation .

What controls should be included when using anti-ERp5 antibodies in experimental research?

When using anti-ERp5 antibodies in experimental research, include the following controls:

• Antibody validation controls:

  • Positive control: Samples known to express ERp5 (e.g., platelet lysates, endoplasmic reticulum fractions)

  • Negative control: Samples from ERp5-knockout models or cells with confirmed ERp5 deletion

  • Isotype control: Matched immunoglobulin (e.g., IgG2b for G-5 monoclonal antibody) to control for non-specific binding

• Expression analysis controls:

  • Loading control: Housekeeping proteins (β-actin, GAPDH) for western blotting

  • Subcellular fraction controls: Markers for ER (calnexin), cytosol, and membrane fractions

• Experimental design controls:

  • Concentration gradient: Testing antibody at multiple concentrations to determine optimal working conditions

  • Cross-reactivity testing: When working with multiple species or closely related proteins (other PDI family members)

  • Secondary antibody-only control: To assess background signal

• Functional assay controls:

  • Wild-type recombinant ERp5 protein (rERp5-wt)

  • Inactive mutant ERp5 protein (rERp5-mut) to distinguish between enzymatic and structural functions

How can ERp5 antibodies be used to investigate immune evasion in cancer research?

ERp5 antibodies provide valuable tools for investigating immune evasion mechanisms in cancer:

• Investigation of MICA/B shedding: ERp5 cleaves NKG2D ligands (NKG2DLs) like MICA from tumor cell surfaces, masking cellular damage and allowing damaged cells to proliferate . Anti-ERp5 antibodies (like clone IA5) can block this cleavage, enabling:

  • Quantification of ERp5-mediated MICA/B shedding

  • Assessment of NKG2D-dependent NK cell recognition

  • Evaluation of immune evasion mechanisms in different cancer types

• Combination therapy assessment: Anti-ERp5 antibodies can be used to investigate the potential of ERp5 as a therapeutic target:

  • Use antibodies to block ERp5 function in combination with immunotherapies targeting NKG2DLs

  • Evaluate enhanced immune recognition of cancer cells

  • Assess the recruitment of NK cells and other immune effectors

• Diagnostic applications: Detection of ERp5 overexpression in various cancers:

  • Hodgkin's lymphoma

  • Multiple myeloma

  • Chronic lymphocytic leukemia

What methodological approaches should be used to study the dual roles of ERp5 in platelet function?

Studies have revealed that ERp5 has dual roles in platelet function, requiring careful methodological approaches:

• Differentiating enzymatic vs. structural functions:

  • Compare effects of wild-type recombinant ERp5 protein (rERp5-wt) vs. inactive mutant ERp5 protein (rERp5-mut)

  • Assess platelet aggregation, granule secretion, and integrin αIIbβ3 activation with both proteins

  • Use binding assays to determine protein-protein interactions independent of enzymatic activity

• Intracellular vs. extracellular ERp5 functions:

  • Intracellular: Study using knockout models and ER stress induction assays

  • Extracellular: Apply exogenous recombinant ERp5 proteins to wild-type platelets

  • Use membrane-impermeable inhibitors to specifically target surface-exposed ERp5

• Assessing bidirectional effects:

  • ERp5 deficiency increases platelet aggregation and thrombus formation (pro-thrombotic)

  • Exogenous rERp5 inhibits platelet aggregation and fibrinogen binding (anti-thrombotic)

  • Employ both in vitro and in vivo assays to capture these opposing effects:

    • In vitro: Platelet aggregation, fibrinogen binding

    • In vivo: Tail bleeding time, FeCl3-induced arterial thrombosis

Research has demonstrated that while platelet-specific ERp5-deficient mice show enhanced platelet reactivity, administration of recombinant ERp5 inhibits platelet aggregation through steric hindrance of integrin αIIbβ3-fibrinogen interaction, independent of its enzymatic activity .

How should researchers address inconsistent results when using anti-ERp5 antibodies in different experimental systems?

When encountering inconsistent results with anti-ERp5 antibodies across experimental systems:

• Antibody validation:

  • Confirm antibody specificity using ERp5-knockout controls

  • Test multiple antibodies targeting different epitopes

  • Validate with orthogonal methods (e.g., mass spectrometry)

• ERp5 isoform consideration:

  • ERp5 exists in multiple isoforms due to alternative splicing

  • Confirm which isoform(s) your antibody detects

  • Use RT-PCR to analyze isoform expression patterns in your model system

• Post-translational modifications:

  • Assess potential differences in ERp5 glycosylation or other modifications

  • Use phosphatase treatment or other enzymatic treatments before analysis

  • Consider enrichment strategies for specific modified forms

• Experimental conditions optimization:

  • Fixation methods significantly impact epitope accessibility in IF/IHC

  • Buffer composition affects antibody-antigen interaction

  • For IHC, use citrate buffer pH 6.0 for optimal epitope retrieval on FFPE tissue sections

• Protein-protein interactions:

  • ERp5 interacts with multiple partners in large chaperone complexes including DnaJ homolog subfamily B member 11, Hsp90b1, GRP78, and others

  • These interactions may mask antibody epitopes in certain contexts

  • Use detergents or crosslinking approaches to address this issue

What are the key considerations when interpreting ERp5 expression data in different cell types and disease states?

When interpreting ERp5 expression data:

• Baseline expression levels:

  • ERp5 expression varies significantly between tissue types

  • Establish appropriate reference/housekeeping genes for each cell type

  • Consider relative vs. absolute quantification methods

• Disease state interpretation:

  • ERp5 overexpression occurs in multiple cancer types including Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia

  • Correlate with other ER stress markers (GRP78, XBP1 splicing, CHOP)

  • Consider the broader context of PDI family expression patterns

• Subcellular localization changes:

  • ERp5 primarily localizes to the ER but can relocalize under stress conditions

  • Surface exposure of ERp5 occurs in activated platelets

  • Use subcellular fractionation or imaging approaches to distinguish pools of ERp5

• Expression pattern in complex systems:

  • In ERp5-deficient platelets, compensatory upregulation of other PDI family members occurs (PDI, ERp57, ERp72, ERp46)

  • Evaluate entire PDI family expression rather than ERp5 alone

  • Consider functional redundancy within the PDI family

• Context-dependent expression regulation:

  • Unlike most PDI family members, ERp5 is not stress-inducible

  • Interpret changes in ERp5 expression differently than other PDIs

  • Evaluate transcriptional vs. post-transcriptional regulation

What emerging techniques should researchers consider for studying ERp5 structure-function relationships?

Researchers should consider these emerging techniques for ERp5 structure-function studies:

• CRISPR-Cas9 domain-specific editing:

  • Generate targeted mutations in specific domains (N-terminal vs. C-terminal CXXC motifs)

  • Create domain-swapped variants with other PDI family members

  • Engineer tagged versions at endogenous loci for live-cell imaging

• Proximity labeling proteomics:

  • Use BioID or APEX2 fusions to identify proximity interactions

  • Map domain-specific interaction networks

  • Identify transient substrate interactions in living cells

• Advanced imaging approaches:

  • Super-resolution microscopy to visualize ERp5 distribution

  • FRET-based sensors to monitor real-time ERp5 activity

  • Correlative light and electron microscopy to link function with ultrastructure

• Structural biology integration:

  • Cryo-EM analysis of ERp5 in complex with substrates

  • Hydrogen-deuterium exchange mass spectrometry to map conformational changes

  • Integrative structural biology combining multiple data types

• Single-cell analysis:

  • Single-cell proteomics to analyze ERp5 expression heterogeneity

  • Spatial transcriptomics to map ERp5 expression in tissue context

  • Multi-omics approaches linking ERp5 expression to functional outcomes

How might targeting ERp5 contribute to novel therapeutic approaches in thrombotic disorders and cancer?

ERp5 presents promising therapeutic potential in both thrombotic disorders and cancer:

• Thrombotic disorder applications:

  • Anti-ERp5 antibodies have been shown to inhibit platelet activation and thrombus formation

  • Recombinant ERp5 protein administration prolonged bleeding times in mice

  • Therapeutic approaches could include:

    • Small molecule inhibitors targeting ERp5's enzymatic activity

    • Peptide-based inhibitors mimicking key interaction surfaces

    • Exogenous administration of recombinant ERp5 as an anti-thrombotic agent

• Cancer immunotherapy applications:

  • Anti-ERp5 antibody (clone IA5) prevents cleavage of NKG2D ligands from tumor cell surfaces

  • This prevents masking of cellular damage and enhances immune surveillance

  • Combinatorial approaches with immune checkpoint inhibitors could enhance:

    • NK cell recognition of tumors

    • CD8+ T cell responses

    • Efficacy of existing immunotherapies

• Dual targeting approaches:

  • Combined targeting of ERp5 and other PDI family members

  • Selective targeting of cell-surface vs. intracellular ERp5 pools

  • Tissue-specific delivery systems to minimize off-target effects

• Biomarker development:

  • ERp5 overexpression as a diagnostic marker in certain cancers

  • Circulating ERp5 levels as potential biomarkers for thrombotic risk

  • ERp5 activity assays as companion diagnostics for targeted therapies